Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities
2019
Immune checkpoint(IC) therapy provides substantial benefits to cancer patients but can also cause distinctive toxicities termed immune-related adverse events (irAEs). Biomarkers to predict toxicities will be necessary to improve management of patients receiving IC therapy. We relied on serological analysis of recombinant cDNA expression libraries to evaluate plasma samples from patients treated with IC therapy and identified
autoantibodies, both in pretreatment and on-treatment samples prior to the development of irAEs, which correlate with the development of immune-related
hypophysitis(anti-GNAL and anti-ITM2B
autoantibodies) and
pneumonitis(anti-
CD74
autoantibody). We developed an enzyme-linked immunosorbent assay and tested additional patient samples to confirm our initial findings. Collectively, our data suggest that
autoantibodiesmay correlate with irAEs related to IC therapy, and specific
autoantibodiesmay be detected early for the management of irAEs.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
42
References
52
Citations
NaN
KQI